Perindopril 2mg/indapamide 0.625 mg. Fixed low-dose combination

Drugs

Volumn 58, Issue 2, 1999, Pages 297-302

  McClellan, Karen J ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

AORTA; CAPILLARY DENSITY; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG MIXTURE; DRUG SAFETY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY FAILURE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL;

EID: 0032780423     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958020-00006     Document Type: Review

References (24)

1. 1. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150: 1175-83
2. 2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
3. 3. Guidelines Subcommittee of WHO-ISH. 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
4. 4. Todd PA, Fitton A. Perindopril: a review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42 (1): 90-114
5. 5. Chaffman M, Heel RC, Brogden RN, et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984; 28: 189-235
6. 6. Ibrahim J, Schachter M, Sever PS, Indapamide/perindopril induced blood pressure lowering and cardiovascular hypertrophy reversal in SHR. J Hum Hypertens 1996 Jun; 10: 438-9
7. 7. Richard V, Joannides R, Henry J-P, et al. Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: haemodynamic, biological and structural effects. J Hypertens 1996 Dec; 14: 1447-54
8. 8. Schiavi P, Brault Y, Carayon A, et al. Dose ranging combination of perindopril and indapamide in the spontaneously hypertensive rat: humoral and hemodynamic effects [abstract]. Am J Hypertens 1997 Apr; 10 (4 Pt 2): 95A
9. 9. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 1997 Oct 7; 96: 2407-13
10. 10. Levy BI, Delafosse JM, Duriez M, et al. Effect of low doses of perindopril and indapamide alone or in combination (Preterax) in renovascular hypertensive rats. Eur Heart J 1999; 1 Suppl. L: L50-57
11. 11. Study report. Servier, Paris, 1999. (Data on file)
12. 12. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997 Jan; 29 (1 Pt 2): 235-41
13. 13. Doucet J, Richard V, Hogie M, et al. Renal effects of combined treatment with low doses of the angiotensin converting enzyme inhibitor perindopril and the diuretic/vasodilator indapamide in spontaneously hypertensive rats [abstract]. Fundam Clin Pharmacol 1996; 10: 186
14. 14. Lachaud-Pettiti V, Lachau-Durand S, Duvauchelle T, et al. Bioequivalence study of combination of indapamide and perindopril administered as one tablet or two capsules after oral single dose [abstract]. Am J Hypertens 1995 Apr; 8 (Pt 2): 181
15. 15. Schiavi P, Piraube C, Lachau-Durand S, et al. Pharmacokinetic evaluation of a potential interaction between perindopril and indapamide at steady-state after once daily administration [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 56A
16. 16. Meyrier A, Dratwa M, Sennesael J. Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Am J Hypertens 1998 Sep; 11: 1087-92
17. 17. Forette B, Laveille C, Lachaud-Pettiti V, et al. Pharmacocinétique de population chez l'hypertendu âgé: évaluation de l'association perindopril + indapamide [abstract]. XVes J Hypertens Artérielle; 1995 Dec 14-15; Paris
18. 18. Myers M, Leenen H, Brault Y, et al. Determination de la dose optimale de perindopril associe a indapamide dans le traitement de l'hypertension arterielle essentielle [abstract]. Arch Mal Coeur Vaiss 1996; 89: 34
19. 19. Forette B, Feldmann L, Laurandin I, et al. Safety and efficacy of a fixed-combination of perindopril and indapamide in 50 elderly hypertensive patients [abstract]. Am J Hypertens 1997 Apr. 10 (4 Pt 2): 111A
20. 20. Castaigne A, Chalmers J, Morgan T. et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Servier 1999. (Data on file)
21. 21. Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very low dose ACE-inhibitor/diuretic combination as first line therapy in elderly hypertensive patients. Servier; 16/4/99. (Data on file)
22. 22. Mallion J-M, Chastang C, Unger P. Efficacy and safety of a fixed low-dose perindopril/indapamide combination in essential hypertension: a randomised controlled study. Servier 1999. (Data on file)
23. 23. Mallion J-M, EURAXI Investigators, Chastang C, et al. Evaluation de l'association fixe a faible dose perindopril 2 mg/indapamide 0.625 mg versus atenolol 50 mg, chez des patients hypertendus, etude randomisee, controlee, en double aveugle [abstract]. Arch Mal Cocur Vaiss 1997; 36: 37
24. 24. Safar M, Salzman V, Brault Y. et al. Safety and efficacy of perindopril/indapamide fixed combination in mild-to-moderate hypertension [abstract]. J Hypertens 1996 Jun; 14 Suppl. 1: 225